| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10624918 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
| US10220049 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
| US9561208 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
| US8288434 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(5 years from now) | |
| US11389467 | BAUSCH | Topical compositions |
Dec, 2040
(16 years from now) | |
Cabtreo is owned by Bausch.
Cabtreo contains Adapalene; Benzoyl Peroxide; Clindamycin Phosphate.
Cabtreo has a total of 5 drug patents out of which 0 drug patents have expired.
Cabtreo was authorised for market use on 20 October, 2023.
Cabtreo is available in gel;topical dosage forms.
Cabtreo can be used as topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older.
The generics of Cabtreo are possible to be released after 28 December, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2026 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2023
Treatment: Topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older
Dosage: GEL;TOPICAL
CABTREO family patents
